Molecular Screening for Lynch Syndrome in Denmark

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01845753

Enrollment

5000

Registered

2013-05-03

Start date

2012-10-31

Completion date

2019-12-31

Last updated

2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, HNPCC, Lynch Syndrome

Brief summary

A clinically applicably strategy for molecular screening for Lynch Syndrome is being implemented in Denmark. Based on sequential analysis with immunohistochemistry and methylation analysis, patients with possible hereditary colorectal cancer are identified. These patients are offered genetic risk assessment and counselling. The study hypothesis is that molecular screening will identify more patients with Lynch Syndrome than the family history alone. Prospective data collection is performed using established clinical databases.

Interventions

OTHERObservation

Observation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Histological diagnosis of colorectal adenocarcinoma * Diagnosed at one of the departments of pathology in Denmark

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Rate of Lynch Syndrome in a population of primary colorectal cancer	1 year

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026